Foundry Book Leverage Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1AMD | ADVANCED MICRO DEVICES INC | Technology | $808.39B | 30.64% |
2PLTR | PALANTIR TECHNOLOGIES INC | Technology | $317.36B | 12.03% |
3SNDK | SANDISK CORP | Technology | $200.63B | 7.60% |
4ISRG | INTUITIVE SURGICAL INC | Healthcare | $122.33B | 4.64% |
5MNST | MONSTER BEVERAGE CORP | Consumer Defensive | $95.36B | 3.61% |
6MPWR | MONOLITHIC POWER SYSTEMS INC | Technology | $64.46B | 2.44% |
7ALAB | ASTERA LABS INC | Technology | $52.04B | 1.97% |
8GRMN | GARMIN LTD | Technology | $48.13B | 1.82% |
9RKLB | ROCKET LAB CORP | Industrials | $39.14B | 1.48% |
10CRDO | CREDO TECHNOLOGY GROUP HOLDING LTD | Technology | $37.80B | 1.43% |
11RDDT | REDDIT INC | Communication Services | $34.88B | 1.32% |
12TWLO | TWILIO INC | Communication Services | $31.38B | 1.19% |
13TPL | TEXAS PACIFIC LAND CORP | Energy | $28.67B | 1.09% |
14ZM | ZOOM COMMUNICATIONS INC | Technology | $26.72B | 1.01% |
15CPRT | COPART INC | Industrials | $25.56B | 0.97% |
16UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 0.86% |
17LSCC | LATTICE SEMICONDUCTOR CORP | Technology | $17.16B | 0.65% |
18SITM | SITIME CORP | Technology | $14.65B | 0.56% |
19ONTO | ONTO INNOVATION INC | Technology | $13.92B | 0.53% |
20PS | PERSHING SQUARE INC | Financial Services | $13.70B | 0.52% |
21MLI | MUELLER INDUSTRIES INC | Industrials | $13.08B | 0.50% |
22GGG | GRACO INC | Industrials | $12.38B | 0.47% |
23AUR | AURORA INNOVATION INC | Technology | $11.88B | 0.45% |
24TECH | BIO-TECHNE CORP | Healthcare | $11.29B | 0.43% |
25RMBS | RAMBUS INC | Technology | $10.97B | 0.42% |
26VICR | VICOR CORP | Technology | $10.83B | 0.41% |
27SMMT | SUMMIT THERAPEUTICS INC | Healthcare | $10.72B | 0.41% |
28KRYS | KRYSTAL BIOTECH INC | Healthcare | $10.46B | 0.40% |
29GMED | GLOBUS MEDICAL INC | Healthcare | $10.45B | 0.40% |
30APGE | APOGEE THERAPEUTICS INC | Healthcare | $10.10B | 0.38% |
31NUVL | NUVALENT INC | Healthcare | $9.79B | 0.37% |
32KYMR | KYMERA THERAPEUTICS INC | Healthcare | $9.52B | 0.36% |
33BMNR | BITMINE IMMERSION TECHNOLOGIES INC | Financial Services | $9.46B | 0.36% |
34PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $9.06B | 0.34% |
35SAIL | SAILPOINT INC | Technology | $8.89B | 0.34% |
36CRNX | CRINETICS PHARMACEUTICALS INC | Healthcare | $8.84B | 0.34% |
37PRAX | PRAXIS PRECISION MEDICINES INC | Healthcare | $8.77B | 0.33% |
38SYRE | SPYRE THERAPEUTICS INC | Healthcare | $8.70B | 0.33% |
39KTOS | KRATOS DEFENSE & SECURITY SOLUTIONS INC | Industrials | $8.63B | 0.33% |
40IMVT | IMMUNOVANT INC | Healthcare | $8.27B | 0.31% |
41FORM | FORMFACTOR INC | Technology | $8.23B | 0.31% |
42PCVX | VAXCYTE INC | Healthcare | $8.12B | 0.31% |
43MBLY | MOBILEYE GLOBAL INC | Consumer Cyclical | $7.76B | 0.29% |
44ZG | ZILLOW GROUP INC | Communication Services | $7.71B | 0.29% |
45TTAN | SERVICETITAN INC | Technology | $7.25B | 0.27% |
46SLAB | SILICON LABORATORIES INC | Technology | $7.17B | 0.27% |
47OKLO | OKLO INC | Utilities | $7.15B | 0.27% |
48CRUS | CIRRUS LOGIC INC | Technology | $6.98B | 0.26% |
49XENE | XENON PHARMACEUTICALS INC | Healthcare | $6.60B | 0.25% |
50APPF | APPFOLIO INC | Technology | $6.36B | 0.24% |
51CGON | CG ONCOLOGY INC | Healthcare | $6.34B | 0.24% |
52QBTS | D-WAVE QUANTUM INC | Technology | $6.19B | 0.23% |
53ERAS | ERASCA INC | Healthcare | $5.96B | 0.23% |
54MBGL | MOBILITY GLOBAL INC | Technology | $5.93B | 0.22% |
55DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.77B | 0.22% |
56VSEC | VSE CORP | Industrials | $5.60B | 0.21% |
57ORKA | ORUKA THERAPEUTICS INC | Healthcare | $5.59B | 0.21% |
58TXG | 10X GENOMICS INC | Healthcare | $5.55B | 0.21% |
59GNTX | GENTEX CORP | Consumer Cyclical | $5.19B | 0.20% |
60VCYT | VERACYTE INC | Healthcare | $4.72B | 0.18% |
61RGTI | RIGETTI COMPUTING INC | Technology | $4.69B | 0.18% |
62MANE | VERADERMICS INC | Healthcare | $4.65B | 0.18% |
63DLB | DOLBY LABORATORIES INC | Industrials | $4.64B | 0.18% |
64UEC | URANIUM ENERGY CORP | Basic Materials | $4.59B | 0.17% |
65IPGP | IPG PHOTONICS CORP | Technology | $4.43B | 0.17% |
66OCTV | OCTAVE INTELLIGENCE PLC | Technology | $4.42B | 0.17% |
67VKTX | VIKING THERAPEUTICS INC | Healthcare | $4.31B | 0.16% |
68EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $4.28B | 0.16% |
69GPGI | GPGI INC | Industrials | $4.21B | 0.16% |
70CALM | CAL-MAINE FOODS INC | Consumer Defensive | $4.20B | 0.16% |
71TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.13B | 0.16% |
72BETA | BETA TECHNOLOGIES INC | Industrials | $4.10B | 0.16% |
73DOCS | DOXIMITY INC | Healthcare | $3.94B | 0.15% |
74POWI | POWER INTEGRATIONS INC | Technology | $3.93B | 0.15% |
75DYN | DYNE THERAPEUTICS INC | Healthcare | $3.92B | 0.15% |
76LASR | NLIGHT INC | Technology | $3.91B | 0.15% |
77CPRX | CATALYST PHARMACEUTICALS INC | Healthcare | $3.85B | 0.15% |
78RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.81B | 0.14% |
79OLED | UNIVERSAL DISPLAY CORP | Technology | $3.75B | 0.14% |
80PAY | PAYMENTUS HOLDINGS INC | Technology | $3.75B | 0.14% |
81ALMS | ALUMIS INC | Healthcare | $3.65B | 0.14% |
82QS | QUANTUMSCAPE CORP | Consumer Cyclical | $3.60B | 0.14% |
83AB | ALLIANCEBERNSTEIN HOLDING LP | Financial Services | $3.54B | 0.13% |
84USAR | USA RARE EARTH INC | Basic Materials | $3.49B | 0.13% |
85XXI | TWENTY ONE CAPITAL INC | Industrials | $3.48B | 0.13% |
86GPCR | STRUCTURE THERAPEUTICS INC | Healthcare | $3.45B | 0.13% |
87ELVN | ENLIVEN THERAPEUTICS INC | Healthcare | $3.24B | 0.12% |
88IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.16B | 0.12% |
89GRAL | GRAIL INC | Healthcare | $3.12B | 0.12% |
90USLM | UNITED STATES LIME & MINERALS INC | Basic Materials | $3.01B | 0.11% |
91MBX | MBX BIOSCIENCES INC | Healthcare | $2.99B | 0.11% |
92XNDU | XANADU QUANTUM TECHNOLOGIES LTD | Technology | $2.98B | 0.11% |
93IRON | DISC MEDICINE INC | Healthcare | $2.91B | 0.11% |
94SMR | NUSCALE POWER CORP | Industrials | $2.82B | 0.11% |
95CLDX | CELLDEX THERAPEUTICS INC | Healthcare | $2.77B | 0.11% |
96VERA | VERA THERAPEUTICS INC | Healthcare | $2.76B | 0.10% |
97VISN | VISTANCE NETWORKS INC | Technology | $2.74B | 0.10% |
98TRVI | TREVI THERAPEUTICS INC | Healthcare | $2.71B | 0.10% |
99NVTS | NAVITAS SEMICONDUCTOR CORP | Technology | $2.68B | 0.10% |
100AEHR | AEHR TEST SYSTEMS | Technology | $2.55B | 0.10% |
101IMNM | IMMUNOME INC | Healthcare | $2.53B | 0.10% |
102RUM | RUMBLE INC | Technology | $2.51B | 0.10% |
103SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $2.45B | 0.09% |
104SPSC | SPS COMMERCE INC | Technology | $2.41B | 0.09% |
105ROG | ROGERS CORP | Technology | $2.36B | 0.09% |
106AGIO | AGIOS PHARMACEUTICALS INC | Healthcare | $2.36B | 0.09% |
107YSS | YORK SPACE SYSTEMS INC | Industrials | $2.33B | 0.09% |
108PVLA | PALVELLA THERAPEUTICS INC | Healthcare | $2.26B | 0.09% |
109MLYS | MINERALYS THERAPEUTICS INC | Healthcare | $2.23B | 0.08% |
110SION | SIONNA THERAPEUTICS INC | Healthcare | $2.23B | 0.08% |
111HTFL | HEARTFLOW INC | Healthcare | $2.15B | 0.08% |
112AXGN | AXOGEN INC | Healthcare | $2.12B | 0.08% |
113PPTA | PERPETUA RESOURCES CORP | Basic Materials | $2.11B | 0.08% |
114RAPP | RAPPORT THERAPEUTICS INC | Healthcare | $2.04B | 0.08% |
115PLSE | PULSE BIOSCIENCES INC | Healthcare | $1.98B | 0.08% |
116INFQ | INFLEQTION INC | Technology | $1.98B | 0.08% |
117AMLX | AMYLYX PHARMACEUTICALS INC | Healthcare | $1.97B | 0.07% |
118DMRA | DAMORA THERAPEUTICS INC | Healthcare | $1.94B | 0.07% |
119TYRA | TYRA BIOSCIENCES INC | Healthcare | $1.91B | 0.07% |
120VRDN | VIRIDIAN THERAPEUTICS INC | Healthcare | $1.86B | 0.07% |
121PRLB | PROTO LABS INC | Industrials | $1.85B | 0.07% |
122SSMR | SUNSHINE MINING & REFINING CO | Basic Materials | $1.83B | 0.07% |
123BCAX | BICARA THERAPEUTICS INC | Healthcare | $1.82B | 0.07% |
124STOK | STOKE THERAPEUTICS INC | Healthcare | $1.81B | 0.07% |
125QUBT | QUANTUM COMPUTING INC | Technology | $1.76B | 0.07% |
126DV | DOUBLEVERIFY HOLDINGS INC | Technology | $1.75B | 0.07% |
127HYMC | HYCROFT MINING HOLDING CORP | Basic Materials | $1.74B | 0.07% |
128GENB | GENERATE BIOMEDICINES INC | Healthcare | $1.74B | 0.07% |
129MPLT | MAPLIGHT THERAPEUTICS INC | Healthcare | $1.72B | 0.07% |
130NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.59B | 0.06% |
131MAZE | MAZE THERAPEUTICS INC | Healthcare | $1.56B | 0.06% |
132AMBQ | AMBIQ MICRO INC | Technology | $1.55B | 0.06% |
133AVBP | ARRIVENT BIOPHARMA INC | Healthcare | $1.55B | 0.06% |
134VIA | VIA TRANSPORTATION INC | Technology | $1.46B | 0.06% |
135INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.46B | 0.06% |
136MRTN | MARTEN TRANSPORT LTD | Industrials | $1.44B | 0.05% |
137AMPX | AMPRIUS TECHNOLOGIES INC | Industrials | $1.44B | 0.05% |
138BLFS | BIOLIFE SOLUTIONS INC | Healthcare | $1.42B | 0.05% |
139AI | C3AI INC | Technology | $1.37B | 0.05% |
140AKTS | AKTIS ONCOLOGY INC | Healthcare | $1.33B | 0.05% |
141DMLP | DORCHESTER MINERALS LP | Energy | $1.31B | 0.05% |
142ABSI | ABSCI CORP | Healthcare | $1.29B | 0.05% |
143IE | IVANHOE ELECTRIC INC | Basic Materials | $1.29B | 0.05% |
144NRP | NATURAL RESOURCE PARTNERS LP | Basic Materials | $1.28B | 0.05% |
145TRAX | FIRST TRACKS BIOTHERAPEUTICS INC | Unclassified | $1.27B | 0.05% |
146CRVS | CORVUS PHARMACEUTICALS INC | Healthcare | $1.25B | 0.05% |
147IRMD | IRADIMED CORP | Healthcare | $1.24B | 0.05% |
148AZTA | AZENTA INC | Healthcare | $1.21B | 0.05% |
149NPKI | NPK INTERNATIONAL INC | Energy | $1.21B | 0.05% |
150CAPR | CAPRICOR THERAPEUTICS INC | Healthcare | $1.13B | 0.04% |
151WVE | WAVE LIFE SCIENCES LTD | Healthcare | $1.12B | 0.04% |
152ORIC | ORIC PHARMACEUTICALS INC | Healthcare | $1.11B | 0.04% |
153CGEM | CULLINAN THERAPEUTICS INC | Healthcare | $1.09B | 0.04% |
154CEVA | CEVA INC | Technology | $1.06B | 0.04% |
155JBIO | JADE BIOSCIENCES INC | Healthcare | $1.03B | 0.04% |
156BIOA | BIOAGE LABS INC | Healthcare | $1.01B | 0.04% |
157OLMA | OLEMA PHARMACEUTICALS INC | Healthcare | $1.00B | 0.04% |
158JANX | JANUX THERAPEUTICS INC | Healthcare | $992M | 0.04% |
159ANRO | ALTO NEUROSCIENCE INC | Healthcare | $967M | 0.04% |
160LWLG | LIGHTWAVE LOGIC INC | Basic Materials | $960M | 0.04% |
161RCAT | RED CAT HOLDINGS INC | Technology | $938M | 0.04% |
162AOSL | ALPHA & OMEGA SEMICONDUCTOR LTD | Technology | $936M | 0.04% |
163RDVT | RED VIOLET INC | Technology | $920M | 0.03% |
164LBRX | LB PHARMACEUTICALS INC | Healthcare | $901M | 0.03% |
165PURR | HYPERLIQUID STRATEGIES INC | Financial Services | $899M | 0.03% |
166TALK | TALKSPACE INC | Healthcare | $873M | 0.03% |
167NPK | NATIONAL PRESTO INDUSTRIES INC | Industrials | $870M | 0.03% |
168SLDB | SOLID BIOSCIENCES INC | Healthcare | $859M | 0.03% |
169NNE | NANO NUCLEAR ENERGY INC | Industrials | $835M | 0.03% |
170AVR | ANTERIS TECHNOLOGIES GLOBAL CORP | Healthcare | $823M | 0.03% |
171UMAC | UNUSUAL MACHINES INC | Industrials | $809M | 0.03% |
172UAMY | UNITED STATES ANTIMONY CORP | Basic Materials | $809M | 0.03% |
173DSGN | DESIGN THERAPEUTICS INC | Healthcare | $785M | 0.03% |
174BBNX | BETA BIONICS INC | Healthcare | $771M | 0.03% |
175MNPR | MONOPAR THERAPEUTICS | Healthcare | $744M | 0.03% |
176CSTL | CASTLE BIOSCIENCES INC | Healthcare | $733M | 0.03% |
177CLYM | CLIMB BIO INC | Healthcare | $727M | 0.03% |
178BBOT | BRIDGEBIO ONCOLOGY THERAPEUTICS INC | Healthcare | $686M | 0.03% |
179PKE | PARK AEROSPACE CORP | Industrials | $677M | 0.03% |
180SGP | SPYGLASS PHARMA INC | Healthcare | $661M | 0.03% |
181MNTN | MNTN INC | Technology | $661M | 0.03% |
182FISN | DEEP FISSION INC | Industrials | $643M | 0.02% |
183LEGH | LEGACY HOUSING CORP | Consumer Cyclical | $637M | 0.02% |
184TECX | TECTONIC THERAPEUTIC INC | Healthcare | $615M | 0.02% |
185RGR | STURM RUGER & CO INC | Industrials | $604M | 0.02% |
186NGNE | NEUROGENE INC | Healthcare | $590M | 0.02% |
187STTK | SHATTUCK LABS INC | Healthcare | $577M | 0.02% |
188FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $575M | 0.02% |
189FLGT | FULGENT GENETICS INC | Healthcare | $573M | 0.02% |
190IMMX | IMMIX BIOPHARMA INC | Healthcare | $558M | 0.02% |
191RLMD | RELMADA THERAPEUTICS INC | Healthcare | $550M | 0.02% |
192XMAX | XMAX INC | Consumer Cyclical | $541M | 0.02% |
193EBF | ENNIS INC | Industrials | $541M | 0.02% |
194CTNM | CONTINEUM THERAPEUTICS INC | Healthcare | $532M | 0.02% |
195ZURA | ZURA BIO LTD | Healthcare | $518M | 0.02% |
196SD | SANDRIDGE ENERGY INC | Energy | $503M | 0.02% |
197GDYN | GRID DYNAMICS HOLDINGS INC | Technology | $484M | 0.02% |
198SGMT | SAGIMET BIOSCIENCES INC | Healthcare | $479M | 0.02% |
199CWCO | CONSOLIDATED WATER CO LTD | Utilities | $467M | 0.02% |
200PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.02% |
201IDR | IDAHO STRATEGIC RESOURCES INC | Basic Materials | $449M | 0.02% |
202SI | SHOULDER INNOVATIONS INC | Healthcare | $448M | 0.02% |
203SRTA | STRATA CRITICAL MEDICAL INC | Industrials | $446M | 0.02% |
204ERII | ENERGY RECOVERY INC | Industrials | $444M | 0.02% |
205DCTH | DELCATH SYSTEMS INC | Healthcare | $442M | 0.02% |
206BNTC | BENITEC BIOPHARMA INC | Healthcare | $439M | 0.02% |
207EVMN | EVOMMUNE INC | Healthcare | $437M | 0.02% |
208ASMB | ASSEMBLY BIOSCIENCES INC | Healthcare | $426M | 0.02% |
209TENX | TENAX THERAPEUTICS INC | Healthcare | $420M | 0.02% |
210NVEC | NVE CORP | Technology | $418M | 0.02% |
211CLFD | CLEARFIELD INC | Technology | $416M | 0.02% |
212SWMR | SWARMER INC | Technology | $410M | 0.02% |
213CBIO | CRESCENT BIOPHARMA INC | Healthcare | $407M | 0.02% |
214SERV | SERVE ROBOTICS INC | Industrials | $394M | 0.01% |
215DMAC | DIAMEDICA THERAPEUTICS INC | Healthcare | $393M | 0.01% |
216UPB | UPSTREAM BIO INC | Healthcare | $382M | 0.01% |
217WEYS | WEYCO GROUP INC | Consumer Cyclical | $374M | 0.01% |
218SLP | SIMULATIONS PLUS INC | Healthcare | $369M | 0.01% |
219ELMD | ELECTROMED INC | Healthcare | $349M | 0.01% |
220MRAM | EVERSPIN TECHNOLOGIES INC | Technology | $341M | 0.01% |
221MPTI | M-TRON INDUSTRIES INC | Technology | $328M | 0.01% |
222BKKT | BAKKT INC | Technology | $323M | 0.01% |
223MSB | MESABI TRUST | Basic Materials | $320M | 0.01% |
224GUACU | BERTO ACQUISITION CORP II | Industrials | $318M | 0.01% |
225SSSS | SURO CAPITAL CORP | Financial Services | $317M | 0.01% |
226OSS | ONE STOP SYSTEMS INC | Technology | $313M | 0.01% |
227GUAC | BERTO ACQUISITION CORP II | Industrials | $311M | 0.01% |
228CIX | COMPX INTERNATIONAL INC | Industrials | $309M | 0.01% |
229OFLX | OMEGA FLEX INC | Industrials | $302M | 0.01% |
230TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $268M | 0.01% |
231ALMU | AELUMA INC | Technology | $267M | 0.01% |
232NSLR | NEOSTELLAR CAPITAL CORP | Financial Services | $266M | 0.01% |
233CNXU | CONEXEU SCIENCES INC | Healthcare | $263M | 0.01% |
234ZSQR | Z SQUARED INC | Healthcare | $260M | 0.01% |
235PCYO | PURE CYCLE CORP | Utilities | $258M | 0.01% |
236LTBR | LIGHTBRIDGE CORP | Industrials | $256M | 0.01% |
237RELL | RICHARDSON ELECTRONICS LTD | Technology | $250M | 0.01% |
238ARTV | ARTIVA BIOTHERAPEUTICS INC | Healthcare | $241M | 0.01% |
239DUOT | DUOS TECHNOLOGIES GROUP INC | Technology | $241M | 0.01% |
240GENC | GENCOR INDUSTRIES INC | Industrials | $235M | 0.01% |
241USAU | US GOLD CORP | Basic Materials | $235M | 0.01% |
242RXST | RXSIGHT INC | Healthcare | $230M | 0.01% |
243UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $222M | 0.01% |
244ATOM | ATOMERA INC | Technology | $218M | 0.01% |
245KROS | KEROS THERAPEUTICS INC | Healthcare | $211M | 0.01% |
246GSIT | GSI TECHNOLOGY INC | Technology | $208M | 0.01% |
247AIRO | AIRO GROUP HOLDINGS INC | Industrials | $205M | 0.01% |
248TNXP | TONIX PHARMACEUTICALS HOLDING CORP | Healthcare | $198M | 0.01% |
249WHG | WESTWOOD HOLDINGS GROUP INC | Financial Services | $188M | 0.01% |
250ACOG | ALPHA COGNITION INC | Healthcare | $185M | 0.01% |
251SBMT | SILVER BOW MINING CORP | Basic Materials | $185M | 0.01% |
252KVHI | KVH INDUSTRIES INC | Technology | $178M | 0.01% |
253TAYD | TAYLOR DEVICES INC | Industrials | $176M | 0.01% |
254AMPG | AMPLITECH GROUP INC | Technology | $168M | 0.01% |
255CRBP | CORBUS PHARMACEUTICALS HOLDINGS INC | Healthcare | $167M | 0.01% |
256LENZ | LENZ THERAPEUTICS INC | Healthcare | $162M | 0.01% |
257CHCI | COMSTOCK HOLDING COMPANIES INC | Real Estate | $162M | 0.01% |
258TRAK | REPOSITRAK INC | Technology | $160M | 0.01% |
259EXOD | EXODUS MOVEMENT INC | Technology | $152M | 0.01% |
260PMN | PROMIS NEUROSCIENCES INC | Healthcare | $136M | 0.01% |
261AXR | AMREP CORP | Real Estate | $136M | 0.01% |
262VTVT | VTV THERAPEUTICS INC | Healthcare | $130M | 0.00% |
263AARD | AARDVARK THERAPEUTICS INC | Healthcare | $128M | 0.00% |
264BUDA | BUDA JUICE INC | Unclassified | $121M | 0.00% |
265AMCI | AMC ROBOTICS CORP | Technology | $114M | 0.00% |
266CODA | CODA OCTOPUS GROUP INC | Industrials | $113M | 0.00% |
267FWACU | FUTUREWAVE ACQUISITION CORP | Industrials | $113M | 0.00% |
268FXACU | FORTUNEX ACQUISITION CORP | Industrials | $110M | 0.00% |
269FXAC | FORTUNEX ACQUISITION CORP | Industrials | $110M | 0.00% |
270USGO | US GOLDMINING INC | Basic Materials | $109M | 0.00% |
271ROC | RANK ONE COMPUTING CORP | Technology | $98M | 0.00% |
272RACD | RESEARCH ALLIANCE CORP IV | Industrials | $95M | 0.00% |
273OPXS | OPTEX SYSTEMS HOLDINGS INC | Industrials | $89M | 0.00% |
274MHH | MASTECH DIGITAL INC | Industrials | $89M | 0.00% |
275RLYB | RALLYBIO CORP | Healthcare | $87M | 0.00% |
276IOR | INCOME OPPORTUNITY REALTY INVESTORS INC | Financial Services | $84M | 0.00% |
277WATT | ENERGOUS CORP | Technology | $83M | 0.00% |
278FRMM | FORUM MARKETS INC | Healthcare | $83M | 0.00% |
279AUC | ATIF HOLDINGS LTD | Financial Services | $82M | 0.00% |
280ROLR | HIGH ROLLER TECHNOLOGIES INC | Consumer Cyclical | $76M | 0.00% |
281ACET | ADICET BIO INC | Healthcare | $76M | 0.00% |
282AGPU | AXE COMPUTE INC | Healthcare | $72M | 0.00% |
283BGSF | BGSF INC | Industrials | $65M | 0.00% |
284IMA | IMAGENEBIO INC | Healthcare | $61M | 0.00% |
285EDSA | EDESA BIOTECH INC | Healthcare | $59M | 0.00% |
286APT | ALPHA PRO TECH LTD | Basic Materials | $53M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $2.64T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 94% toward Large, 90% toward Growth. +1% unclassified (14 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 286 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual64.7%Margin-10.3%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual30.6%Margin-5.6%The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).
Required<= 25.0%Actual42.3%Margin-17.3%Days required to liquidate the largest position at 20% of one day's dollar volume.
Required<= 7.0 daysActualunboundedMargin—
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 286 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators disagree about the verdict, not just the value — the choice of method decides the answer here. Historical VaR gives ratio 2.05 (fail) but Gaussian VaR gives 1.77 (pass). The pass/fail conclusion is an artefact of estimator choice, not a property of the strategy.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 30.3% | 9.1% |
| 3 yearsp.a. | 20.1% | -2.1% |
| 5 yearsp.a. | 1.8% | -11.0% |
| 10 yearsp.a. | 9.1% | -6.2% |
| Since inceptionp.a. | 5.8% | -3.1% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 15.3% | 6.3% |
| 2025 | 27.8% | 5.3% |
| 2024 | 11.3% | -14.7% |
| 2023 | 27.8% | 7.1% |
| 2022 | -40.5% | -28.6% |
| 2021 | -7.9% | -35.6% |
| 2020 | 36.8% | 26.4% |
| 2019 | 35.1% | 2.3% |
| 2018 | -15.9% | -3.8% |
| 2017 | 37.1% | 6.5% |
| 2016 | 3.4% | -15.3% |
| 2015 | 18.4% | 19.7% |
| 2014 | 17.3% | 5.1% |
| 2013 | 43.6% | -3.4% |
| 2012 | 8.8% | -18.8% |
| 2011 | 0.6% | 16.7% |
| 2010 | 11.3% | -0.1% |
| 2009 | 58.6% | 21.0% |
| 2008 | -41.6% | 20.9% |
| 2007 | 19.4% | 44.8% |
| 2006 | 1.7% | -16.1% |
| 2005 | 10.7% | 4.5% |
| 2004 | 15.8% | 2.7% |
| 2003 | 48.6% | 8.0% |
| 2002 | -36.1% | -24.8% |
| 2001 | -47.8% | -41.3% |
| 2000 | -51.1% | -61.3% |
| 1999 | 119.5% | 98.6% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Book Leverage Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks (price > $5, market-cap floor) each month by a Book Leverage signal and holds the top decile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.